Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Drone Video of the Year is stunning – you've not seen Namibia like this - 2Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- 3When a sperm whale gives birth, the mother gets help from her friends
- 4Two UN peacekeepers killed in explosion in Lebanon
- 5A mom stopped giving her kids snacks — and sparked a debate about eating habits
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- In these U.S. groups, deaths now exceed births. What’s happening?
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- Visual communication Programming for Fledglings
- NASA shares first photos of Earth taken by Artemis II
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
